MoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75

AI Briefing

• – MoonLake Immunotherapeutics announces strong Week 40 results from its Phase 3 VELA programs in hidradenitis suppurativa, with 62% of patients achieving HiSCR75.
• – Clinical responses continued to improve beyond the initial 16-week primary endpoint.
• – Results show potential for sustained long-term benefit in patients with hidradenitis suppurativa.